Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(14 sites)
China
The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, Anhui China-Japan Friendship Hospital, Beijing, Beijing Municipality The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality The First Hospital of Hebei Medical Universtiy, Shijiazhuang, Hebei Henan Cancer Hospital, Zhengzhou, Henan Zhongnan Hospital of Wuhan University, Wuhan, Hubei The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Sheng Jing Hospital of China Medical Universtiy, Shenyang, Liaoning Huashan Hospital Affiliated to Fudan University, Shanghai, Shanghai Municipality Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin Municipality The Second Hospital of Tianjin Medical Universtiy, Tianjin, Tianjin Municipality The First Affilicated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang